Published in Gene Therapy Weekly, February 21st, 2002
Under the terms of the agreement, Innogenetics will use the PER.C6 platform to develop monoclonal antibodies in the context of its therapeutic programs, and will be able to manufacture and market the emerging therapeutic products.
Crucell's CEO Dinko Valerio welcomes Innogenetics as its launching customer for antibody production. "We are delighted with Innogenetics' choice for our technology in the context...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.